Food & function
Cure8 research brief
Why This Matters
The study suggests a new microbiome-based strategy that targets toxic hydrogen sulfide production and boosts host detoxification — a mechanism potentially relevant to some forms of IBD driven by sulfur-metabolizing pathobionts.
Who Should Pay Attention
Researchers, clinicians interested in microbiome therapies, and patients following probiotic or microbiome research.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper (abstract) reports that a probiotic strain, Lactobacillus brevis ZFM820, modulates intestinal sulfur metabolism to reduce sulfide-driven colitis in experimental models.
According to the abstract, the strain produces phenyllactic acid to inhibit pathogenic sulfate-reducing bacteria and promotes expansion of beneficial butyrate-producing bacteria, which together increase host sulfide-detoxifying enzymes and restore barrier function.
The study frames the approach as targeting an ecological metabolic imbalance — reducing toxic hydrogen sulfide production while boosting host detoxification — and emphasizes that live ZFM820, not isolated metabolites, is required for the combined effect.
This is reported in the abstract of a basic-science journal article; details on models, methods, and safety in humans are not provided in the abstract and would require reading the full paper.
Keep In Mind
Abstract-level report; preclinical/basic-science findings. Human safety and clinical efficacy are not established in this abstract.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFood & function
AuthorsYonglu Li, Chen Yang, Lujing Li +6 more
InstitutionSchool of Food Science and Biotechnology, Zhejiang Gongshang University, Hangzhou 310018, Zhejiang, People's Republic of China. guqing@zjgsu.edu.cn.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 14, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Extracellular vesicles from pasteurized Akkermansia muciniphila ameliorate inflammatory bowel disease through suppression of STING-driven inflammatory signaling.
This study suggests a new, non‑live (“postbiotic”) approach—extracellular vesicles from pasteurized Akkermansia muciniphila—may reduce inflammation and improve barrier function in an experimental colitis model, which...
Unraveling the probiotic evidence: how Lactobacillus pentosus from fermented vegetables alleviates colitis by enlisting muribaculum to boost host phosphatidylcholine biosynthesis.
This study identifies a specific probiotic–commensal interaction that improved colitis in mice and points to a metabolite (phosphatidylcholine) and metabolic pathway that might help repair the gut barrier — a pathway...
Oral Nanoarmored Lactobacillus rhamnosus with Inflammation Targeting and Scavenging Activities for Colitis Lesion-Specific Therapy
This work describes a novel engineered probiotic designed to survive the gastrointestinal tract and act specifically at inflamed colitis sites, which could lead to new targeted therapies for IBD if validated in humans.